Revenue from Contract with Customer [Text Block]

Revenue

Disaggregation of revenue

In the following tables, revenue is disaggregated by primary geographical markets and major goods and service lines.


	Reportable Segments
	Three Months Ended
	June 30, 2024						July 2, 2023
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	168,413	$	139,370	$	307,783	$	184,795	$	134,032	$	318,827
Europe	67,358		117,230		184,588		74,707		116,910		191,617
Asia	78,076		121,238		199,314		76,851		121,771		198,622
	$	313,847	$	377,838	$	691,685	$	336,353	$	372,713	$	709,066

Major goods/service lines
Life Sciences reagents	$	176,852	$	—	$	176,852	$	192,208	$	—	$	192,208
Life Sciences instruments	86,252		—		86,252		100,101		—		100,101
Life Sciences software	50,743		—		50,743		44,044		—		44,044
Reproductive health	—		129,175		129,175		—		128,621		128,621
Applied genomics	—		51,287		51,287		—		59,097		59,097
Immunodiagnostics	—		197,376		197,376		—		184,995		184,995
	$	313,847	$	377,838	$	691,685	$	336,353	$	372,713	$	709,066


	Reportable Segments
	Six Months Ended
	June 30, 2024						July 2, 2023
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	324,741	$	277,396	$	602,137	$	348,649	$	272,206	$	620,855
Europe	137,003		226,147		363,150		154,992		221,522		376,514
Asia	155,140		221,178		376,318		161,153		225,409		386,562
	$	616,884	$	724,721	$	1,341,605	$	664,794	$	719,137	$	1,383,931

Major goods/service lines
Life Sciences reagents	$	354,077	$	—	$	354,077	$	382,086	$	—	$	382,086
Life Sciences instruments	167,162		—		167,162		196,275		—		196,275
Life Sciences software	95,645		—		95,645		86,433		—		86,433
Reproductive health	—		253,050		253,050		—		250,742		250,742
Applied genomics	—		98,734		98,734		—		122,507		122,507
Immunodiagnostics	—		372,937		372,937		—		345,888		345,888
	$	616,884	$	724,721	$	1,341,605	$	664,794	$	719,137	$	1,383,931

Contract Balances

Contract assets: The unbilled receivables (contract assets) primarily relate to the Company’s right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in “Accounts receivable, net” in the condensed consolidated balance sheets.

Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related services for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in “Accounts payable” or “Accrued expenses and other current liabilities” or as long-term in “Long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The contract liability balances at the beginning of each period presented were generally fully recognized in the subsequent three month period. The performance obligations that are unsatisfied (or partially unsatisfied) at the end of each period presented are not material to the Company.

Contract balances were as follows: